Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvedBy |
gptkb:FDA
2008 (US) |
| gptkbp:ATCCode |
N05AB14
|
| gptkbp:brand |
gptkb:Nitoman
gptkb:tetrabenazine Motetis |
| gptkbp:CASNumber |
58-46-8
|
| gptkbp:chemicalFormula |
C19H27NO3
|
| gptkbp:contraindication |
active suicidal ideation
untreated or inadequately treated depression |
| https://www.w3.org/2000/01/rdf-schema#label |
Xenazine
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Lundbeck
|
| gptkbp:mechanismOfAction |
VMAT2 inhibitor
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:depression
insomnia drowsiness parkinsonism |
| gptkbp:usedFor |
treatment of chorea associated with Huntington's disease
|
| gptkbp:bfsParent |
gptkb:Bausch_Health_Companies_Inc.
gptkb:tetrabenazine gptkb:Valeant_Pharmaceuticals_International |
| gptkbp:bfsLayer |
7
|